<DOC>
	<DOC>NCT02047461</DOC>
	<brief_summary>This study will include a screening period, a 6-month treatment period, and a 60-month, long-term extension period.</brief_summary>
	<brief_title>Safety &amp; Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP</brief_title>
	<detailed_description>Patients will receive daily IV infusions of ALXN1101 starting on Day 1. After a prescribed period, dosing will increase monthly based on defined patient safety measures. After Month 6, patients will continue daily dosing through Month 66 at their last tolerated dose.</detailed_description>
	<mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Molybdenum</mesh_term>
	<criteria>Male or female patients with a genetically confirmed diagnosis of MoCD Type A (MOCS1 mutation) Currently treated with rcPMP infusions Current or planned treatment with another investigational drug or device, with the exception rcPMP treatment through Day 1.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Molybdenum cofactor deficiency (MoCD)</keyword>
	<keyword>molybdenum cofactor (MoCo) biosynthesis</keyword>
	<keyword>sulfite oxidase (SO)</keyword>
	<keyword>xanthine dehydrogenase</keyword>
	<keyword>aldehyde oxidase</keyword>
	<keyword>S sulfocysteine (SSC)</keyword>
</DOC>